Ga-DOTATATE PET in neuroectodermal tumours: First experience

Nuclear Medicine Communications

Volumn 28, Issue 5, 2007, Pages 359-363

  Win, Zarni ^a   Al Nahhas, Adil ^a   Towey, David ^a   Todd, Jeannie F ^b   Rubello, Domenico ^b   Lewington, Val ^c   Gishen, Philip ^c  

^a Departments of Nuclear Medicine   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Phaeochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; OCTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLTYROSYLTHREONINE GA 68]; TRACER; UNCLASSIFIED DRUG;

CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FEMALE; HUMAN; MALE; NEUROECTODERM TUMOR; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; REVIEW;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; FEMALE; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PHEOCHROMOCYTOMA; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34147093265     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32808ea0b0     Document Type: Article

References (32)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-1320.
2. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2:851-856.
3. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458-460.
4. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993; 34:173-179.
5. Jalil ND, Pattou FN, Combemale F, Chapuis Y, Henry JF, Peix JL, Proye CA. Effectiveness and limits of pre-operative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. Eur J Surg 1998; 164:23-28.
6. Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PM, Ross G, et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med 1987; 28:973-978.
7. Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R, et al. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology 1985; 155:789-792.
8. rd E, Alavi A. The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma. J Nucl Med 1994; 35:1138-1144.
9. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147:1-10.
10. 111In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2000; 86:685-693.
11. Maurea S, Lastoria S, Caraco C, Klain M, Varrella P, Acampa W, et al. The role of radiolabeled somatostatin analogs in adrenal imaging. Nucl Med Biol 1996; 23:677-680.
12. Steinert H, Lehnert H, Bockisch A, Beyer J, Hahn K. Detection of malignant pheochromocytoma tumor sites by 111-In-octreotide scintigraphy. Eur J Nucl Med 1993; 20:843.
13. Hoefnagel CA. MIBG and radiolabeled octreotide in neuroendocrine tumors. Q J Nucl Med 1995; 39:137-139.
14. Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, et al. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q J Nucl Med 1995; 39:145-149.
15. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier C. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995; 36:1-6.
16. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 1997; 46:39-44.
17. Limouris GS, Giannakopoulos V, Stavraka A, Toubanakis N, Vlahos L. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 MIBG scintimaging in neural crest tumors. Anticancer Res 1997; 17:1589-1592.
18. 111In-DTPA0] octreotide in patients. Eur J Nucl Med 2001; 28:1319-1325.
19. Behe M, Maecke H. New somatostatin analogs labelled with technetium-99m [Abstract]. Eur J Nucl Med 1995; 22:791.
20. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28:1751-1757.
21. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5:42-48.
22. Lewigton VJ. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 2003; 10:497-501.
23. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003; 88:4083-4087.
24. 123I]iodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006; 27:31-36.
25. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F] fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38:6-8.
26. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992; 33:1125-1131.
27. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001; 12:469-475.
28. 18F DOPA whole-body PET - initial results. Radiology 2002; 222:507-512.
29. Shulkin BL, Roberts EG, Raffel DM, Gauger PA, Wieland DW, et al. Carbon-11 epinephrine PET imaging of phaeochromocytomas. J Nucl Med 2003; 44(suppl):297.
30. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Phaeochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212:35-41.
31. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46 (Suppl 1):62S-66S.
32. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labeling with various radiometals. Eur J Nucl Med 2003; 30:1338-1347.